氟伏沙明治疗青少年强迫症对照研究

目的探讨氟伏沙明治疗青少年强迫症的临床疗效和安全性。方法将60例青少年强迫症患者随机分为两组各30例，研究组口服氟伏沙明治疗，对照组口服氯米帕明治疗。观察8w。于治疗前及治疗2w、4w、6w、8w末采用强迫量表评定临床疗效，副反应量表评定不良反应。结果治疗第2w末起两组强迫量表总分均较治疗前有显著下降（P〈0．01），而减分率呈持续性升高；同期两组间比较均无显著性差异（P〉0．05）。治疗8w末研究组显效率为60．0％，有效率为86．7％；对照组为56．7％和83．3%，两组无显著性差异（P〉0．05）。研究组不良反应较轻微，发生率显著低于对照组（P〈0．05）。结论氟伏沙明治疗青少年强迫症疗效与氯米帕明相当，但较氯米帕明安全性更高、依从性更好。

A control study of fluvoxamine in the treatment of adolescence obsessive-compulsive disorder

Objective To explore the clinical efficacy and safety of fluvoxamine in the treatment of adolescence obsessive-compulsive disorder（AOCD）. Methods 60 AOCD patients were randomly divided into two groups of 30 ones each, research group took orally fluvoxamine and control group did clomipramine for 8 weeks. Clinical efficacies were assessed with the Yale-Brown Obsessive Compulsive Scale （Y-BOCS） and adverse reactions with the Treatment Emergent Symptom Scale （TESS） before treatment and at the end of the 2nd, 4th, 6th and 8th week. Results Since the end of the 2nd week, the toatl scores of the Y-BOCS of both groups lowered more significantly compared with pretreatment （P〈0. 01）; score-decrement rates heightened continously; there were no significant differences in synchronization group comparisons（P〉0. 05）. At the end of the 8th week, obvious effective and effective rates were respectively 60.0% and 86.7% in the research and 56.7% and 83.3% in the control group,which showed no significant differences （P〉0. 05）. Adverse reactions were mild and their incidences significantly lower in the research than in the control group（P〈0. 05）. Conclusion Fluvoxamine has an ecident effect equivalent to clomipramine in the treatment of adolescence OCD,but higher safety and better compliance than clomipramine.